Wisp Acquires Sexual Health Platform TBD Health
This is Wisp’s first acquisition, for which the terms of the deal were not disclosed. It allows the company to expand into providing in-person care to complement its virtual support.
Worldwide Clinical Trials to Buy Catalyst, Another M&A Deal Between Private Equity-Backed CROs
The contract research organization consolidation trend continues with Worldwide Clinical Trials striking a deal for Catalyst Clinical Research, which has particular expertise in oncology. Worldwide is a portfolio company of Kohlberg, a private equity firm.
NEMT Partner Guide: Why Payers and Providers Should Choose MediDrive’s TMS
Alan Murray on improving access for medical transportation.
GSK Grows in Immunology, Buying Rapt Therapeutics and Food Allergy Drug in $2.2B Deal
Rapt Therapeutics brings to GSK ozureprubart, a long-acting antibody that inhibits the validated immunology target immunoglobulin E (IgE). If GSK is able to bring this drug to the market, it would complete with the blockbuster Genentech and Novartis allergy drug Xolair.
Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition
Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular disease and Parkinson’s disease. Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity.
J.P. Morgan Report: Obesity & Diabetes Dealmaking Set a New Record in 2025
Obesity and diabetes drug R&D partnerships struck in 2025 represented $20.2 billion in total deal value, a new record high, according to a new report from J.P. Morgan. While IPO activity and venture investment trended downward, M&A activity was significantly higher.
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition
Dynavax Technologies brings Sanofi a commercialized hepatitis B vaccine and a clinical-stage shingles vaccine, both of which offer differentiation from products marketed by GSK. It's Sanofi’s second billion-dollar vaccines acquisition of 2025.
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition
BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers.
Sobi Grows Its Gout Drug Prospects With $950M Acquisition of Startup Arthrosi Therapeutics
Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment.
Merck Makes Big Antiviral Move With $9B Deal to Land Cidara’s Late-Stage Drug for Flu Prevention
Merck’s Cidara Therapeutics acquisition brings a lead program with potential to become a first-in-class drug for preventing influenza infection. A Phase 3 study is already underway, timed to coincide with the start of the flu season in the Northern Hemisphere.
Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera
Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favor, ending a bidding war for Metsera and its next-generation obesity medications.
presented by
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal
Pfizer claims Metsera breached their merger agreement, adding that a tie-up of the biotech with GLP-1 drug giant Novo Nordisk would violate U.S. antitrust law. Metsera called the arguments “nonsense” and said Pfizer is trying to buy the obesity drug developer for less than what Novo is willing to pay.
Thermo Fisher Expands Biopharma Offerings With $9B Deal for Clinical Trial Software Firm Clario
Private equity-backed Clario brings to Thermo Fisher Scientific software that collects, manages, and analyzes clinical trial endpoint data. Analysts see Clario’s offerings as highly complementary to PPD, the contract research organization that Thermo Fisher acquired in 2021.
Novo Nordisk Swoops In With $6.5B Bid to Top Pfizer’s M&A Deal With Obesity Biotech Metsera
Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the obesity drug developer for $4.9 billion. Novo Nordisk, a finalist in that pursuit, is positioning itself as a deal spoiler with a new unsolicited offer that shells out much more upfront cash.
Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition
Avidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver.
BioCryst’s $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE
BioCryst Pharmaceuticals’ Astria Therapeutics acquisition brings navenibart, a drug in Phase 3 testing for the rare disease hereditary angioedema. The injectable antibody has the potential to match the efficacy of the blockbuster Takeda Pharmaceutical drug that currently dominates the market, but with less burdensome dosing that could encourage HAE patients to switch.